Bonnee Binker and Paul Motenko to lead efforts in Washington, D.C., for volunteer conference, teamMATEs: Together Until It's Done.
Site Search
The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
This week, Congress approved a budget resolution that will allow lawmakers to make certain changes to the Affordable Care Act and Medicaid.
Complications of cystic fibrosis affect everyone with the disease, regardless of their mutation. We are supporting research into CF complications, such as infections, inflammation, excessive mucus, and gastrointestinal issues, to develop better treatments and improve outcomes for people with CF.
This week, Congress approved a budget resolution that will allow lawmakers to make certain changes to the Affordable Care Act and Medicaid.